Tabula Rasa HealthCare (TRHC) Posts Wider Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Tabula Rasa HealthCare Reports First Quarter 2022 Results
May 5, 2022 4:03 PM EDTFirst quarter 2022 revenue of $67.1 million from continuing operations includes CareVention HealthCare revenue of $66.3 million, up 19% vs. a year agoPlanned sales of PrescribeWellness, SinfonÃaRx, and DoseMe expected to add significant liquidity, reduce net debt, and provide financial flexibilityGAAP net loss from continuing operations of $20.4 millionAdjusted EBITDA of $2.5 million
MOORESTOWN, N.J., May 5, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC", the "Company," "we," "us," or "our") (Nasdaq: TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first... More



